1990—2020年全球、区域及国家痛风负担及2050年预测:2021年全球疾病负担研究的系统分析
基于2021年全球疾病负担研究,整合35个国家人群数据及美国和中国台湾地区索赔数据,采用嵌套贝叶斯荟萃回归模型估计1990—2020年痛风患病率和伤残损失寿命年,并用混合效应模型预测至2050年。
要点
- 2020年男性痛风患病率为女性的3.26倍,患病率随年龄增长而升高。
- 高体重指数归因于34.3%的痛风伤残损失寿命年,肾功能障碍归因于11.8%。
核心结论
- 预测模型估计2020年至2050年痛风患者数将增加超过70%,主要归因于人口增长和老龄化。
- 鉴于痛风残疾与高体重指数的关联,需要在人群层面开展以减重为重点的饮食和生活方式干预,并保障痛风发作预防和控制干预的可及性。
研究设计与样本
- 基于2021年全球疾病负担研究,利用35个国家的人群数据及美国和中国台湾地区的索赔数据估计1990—2020年痛风患病率和伤残损失寿命年。
- 采用嵌套贝叶斯荟萃回归模型按年龄、性别和地区估计患病率和伤残损失寿命年,并用混合效应模型预测至2050年的患病率。
主要发现
- 2020年全球痛风患病率男性为女性的3.26倍(3.11—3.39),且随年龄增长而升高。
- 2050年年龄标化痛风患病率预测为每10万667例(531—830)。
- 2020年全球痛风年龄标化伤残损失寿命率为每10万20.5例(14.4—28.2);高体重指数归因于34.3%(27.7—40.6)的痛风伤残损失寿命年,肾功能障碍归因于11.8%(9.3—14.2)。
临床怎么用
- 作者认为,需要在人群层面开展以减重为重点的饮食和生活方式干预,并保障痛风发作预防和控制干预的可及性,以减轻痛风负担。
- 作者强烈鼓励收集严重程度和残疾估计数据,以纳入未来的全球疾病负担研究迭代。
局限性
- 尽管采用了标准化的全球疾病负担方法和建模,但在许多国家尤其是低收入和中等收入国家,估计基于模型而非原始数据,且缺乏严重程度和残疾估计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Gout is an inflammatory arthritis manifesting as acute episodes of severe joint pain and swelling, which can progress to chronic tophaceous or chronic erosive gout, or both. Here, we present the most up-to-date global, regional, and national estimates for prevalence and years lived with disability (YLDs) due to gout by sex, age, and location from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021, as well as forecasted prevalence to 2050. METHODS: Gout prevalence and YLDs from 1990 to 2020 were estimated by drawing on population-based data from 35 countries and claims data from the USA and Taiwan (province of China). Nested Bayesian meta-regression models were used to estimate prevalence and YLDs due to gout by age, sex, and location. Prevalence was forecast to 2050 with a mixed-effects model. FINDINGS: In 2020, 55·8 million (95% uncertainty interval 44·4-69·8) people globally had gout, with an age-standardised prevalence of 659·3 (525·4-822·3) per 100 000, an increase of 22·5% (20·9-24·2) since 1990. Globally, the prevalence of gout in 2020 was 3·26 (3·11-3·39) times higher in males than in females and increased with age. The total number of prevalent cases of gout is estimated to reach 95·8 million (81·1-116) in 2050, with population growth being the largest contributor to this increase and only a very small contribution from the forecasted change in gout prevalence. Age-standardised gout prevalence in 2050 is forecast to be 667 (531-830) per 100 000 population. The global age-standardised YLD rate of gout was 20·5 (14·4-28·2) per 100 000 population in 2020. High BMI accounted for 34·3% (27·7-40·6) of YLDs due to gout and kidney dysfunction accounted for 11·8% (9·3-14·2). INTERPRETATION: Our forecasting model estimates that the number of individuals with gout will increase by more than 70% from 2020 to 2050, primarily due to population growth and ageing. With the association between gout disability and high BMI, dietary and lifestyle modifications focusing on bodyweight reduction are needed at the population level to reduce the burden of gout along with access to interventions to prevent and control flares. Despite the rigour of the standardised GBD methodology and modelling, in many countries, particularly low-income and middle-income countries, estimates are based on modelled rather than primary data and are also lacking severity and disability estimates. We strongly encourage the collection of these data to be included in future GBD iterations. FUNDING: Bill & Melinda Gates Foundation and the Global Alliance for Musculoskeletal Health.
引用
- Global, regional, and national burden of gout, 1990-2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021. Lancet Rheumatol. 2024. PMID: 38996590. doi:10.1016/S2665-9913(24)00117-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。